Decitabine

AML/MDS

Stichting Hemato-Oncologie voor Volwassenen NederlandSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

10 Active assets in the AML/MDS cohort.

Asset / Sponsor	Phase	Rating
Midostaurin Stichting Hemato-Oncologie voor Volwassenen Nederland	Phase 2	CCC
Azacitidine Newave Pharmaceutical Inc	Phase 1	CC
lp-108 Newave Pharmaceutical Inc	Phase 1	CC
Cyclophosphamide St. Jude Children's Research Hospital	Phase 1	CC
Mana 312 Mana Therapeutics	Phase 1	CC

View all 13 →

Same molecule, other indications

Decitabine is also rated in:

disease related to hematopoietic stem cell transplantDormant

BBB

Indicative ·

72 / 100

acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant

BB

Indicative ·

70 / 100

acute myeloid leukemiaDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.